Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

908 Devices’ Research Partner Presents Research on Mass Spectrometry

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Advancing the rapidly evolving field of High Pressure Mass Spectrometry.

908 Devices continues to benefit from its research partnership with the group of Prof. J. Michael Ramsey at the University of North Carolina at Chapel Hill (UNC-CH).

The Ramsey team made a total of eight research presentations at the American Society of Mass Spectrometry Conference in June, all advancing the rapidly evolving field of High Pressure Mass Spectrometry (HPMS™).

The UNC-CH presentations covered substantial advances in both the theoretical understanding and practical performance of miniature ion traps, ionizers and detectors at operating pressures up to, and beyond, 1 torr - HPMS™.

Multiple presentations explored the theoretical attributes of ion trajectories as a function of trap fabrication geometries and drive parameters.

One of the most exciting areas of research involves a new stretched length ion trap geometry that experimentally demonstrated a near order-of-magnitude increase in ion-trapping capacities compared to cylindrical geometries.

Further, a presentation on the influence of drive frequency demonstrated sub-amu resolutions from miniature ion trap arrays operating in the HPMS regime.

908 Devices has exclusive license to a broad portfolio of patents developed by the research team at the University that contributes to the design and manufacture of simple-to-operate, ultra-compact chemical detection and analysis tools.

The HPMS™ projects presented by the Ramsey group received support from the US Department of Defense (DOD) signifying the value placed on these capabilities by the safety and security community.

Dr. Chris Brown, Co-founder and CTO of 908 Devices highlighted the impressive nature of the research presented by saying, “The Ramsey group at UNC-CH has a large, focused and productive effort in the field of miniaturized mass spectrometry. Collaboration between our teams continues to be mutually beneficial and we are extremely excited about working together to successfully bring the powerful capabilities of mass spectrometry out of the laboratory into the hands of the first responder.”

These HPMS developments are crucial to the successful creation of highly sensitive and selective miniaturized mass spectrometry tools by 908 Devices.

The initial product focus is on safety and security markets, but the broad platform of 908 Devices’ simple, rugged and cost-effective MS analyzers will address customer problems across diverse markets.

The UNC-CH research team is led by Professor J. Michael Ramsey, who is the Minnie N. Gold by Distinguished Professor of Chemistry in UNC-CH’s College of Arts and Sciences, at the University with additional multiple appointments in the UNC-CH School of Medicine.

Prof. Ramsey is also a co-founder of 908 Devices, a member of its Board of Directors and the Science Founder of Caliper Life Sciences.

“Our presentations outlined clearly a number of innovative advances in miniaturized mass spectrometry, a dynamic field with myriad practical applications outside the lab,” said Prof. Ramsey.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

908 Devices Announces Significant Milestones
Company has expanded its office from a 7,000 square-foot R&D think tank into a 16,000 square-foot full-scale production facility.
Wednesday, August 20, 2014
908 Devices Receives $7 Million in Series B Funding
The financing round will be used to expand the R&D team and to accelerate and commercialize 908 Devices’ initial safety and security products.
Wednesday, September 11, 2013
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!